Given Biofrontera's history of not meeting EPS estimates and the subsequent negative reactions in its stock price, it's likely that the upcoming earnings report could have a similar negative impact, especially if the company fails to meet or exceed the EPS estimate again. The significant year-to-date decline in share price further emphasizes the stock's sensitivity to earnings reports and guidance.